← The Wire
XLONasdaq
Xilio Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1840233
Xilio Therapeutics develops masked immuno-oncology therapies activated within tumors to treat cancer effectively and safely
red 8-K · 90d
$55M
Market cap
$9.27
Last close
+2.4%
1D
+3.7%
5D
156K
Volume
Price · last 39 sessions+11.3%
May 4L $7.68 · H $9.27Jun 29
119
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 12, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 2026DEF 14ADEF 14AApr 28, 20268-KExecutive ChangeApr 16, 202610-K10-KMar 23, 20268-KResults of OperationsMar 23, 20268-KSecurity-Holder Rights · Bylaw AmendmentMar 12, 20268-KReg FD DisclosureMar 9, 20268-KShareholder VoteFeb 24, 20268-KMaterial Agreement · Reg FD DisclosureFeb 12, 2026424B5424B5Feb 12, 2026424B5424B5Feb 11, 2026DEF 14ADEF 14AJan 26, 20268-KExecutive Change · Results of OperationsJan 8, 20268-KReg FD DisclosureJan 5, 20268-KExecutive Change · Shareholder VoteNov 25, 202510-Q10-QNov 13, 20258-KResults of OperationsNov 13, 20258-KReg FD DisclosureNov 7, 2025DEF 14ADEF 14AOct 20, 20258-KDelisting NoticeOct 3, 20258-KCompany UpdateSep 9, 20258-KDelisting NoticeAug 28, 202510-Q10-QAug 14, 20258-KResults of OperationsAug 14, 20258-KShareholder VoteJun 12, 20258-KExecutive ChangeJun 10, 2025DEFA14ADEFA14AJun 3, 20258-KMaterial Agreement · Reg FD DisclosureJun 3, 2025424B5424B5Jun 3, 2025424B5424B5Jun 2, 20258-KReg FD Disclosure · Company UpdateJun 2, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KDelisting NoticeApr 8, 20258-KMaterial AgreementMar 11, 2025424B5424B5Mar 11, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KMaterial Agreement · Equity IssuanceFeb 12, 20258-KReg FD Disclosure · Company UpdateJan 21, 20258-KEquity Issuance · Reg FD DisclosureDec 19, 202410-Q10-QNov 7, 20248-KResults of Operations · Reg FD DisclosureNov 7, 2024SC 13GGKCC SCHEDULE 13GSep 27, 20248-KDelisting NoticeSep 13, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KShareholder VoteJun 17, 20248-KExecutive ChangeJun 13, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 2024424B5424B5Apr 15, 202410-K10-KApr 1, 20248-KResults of OperationsApr 1, 20248-KCompany UpdateMar 28, 20248-KMaterial Agreement · Results of OperationsMar 28, 2024SC 13GSC 13GFeb 14, 20248-KDelisting NoticeJan 19, 20248-KExecutive ChangeJan 3, 20248-KCompany UpdateDec 7, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 202310-Q/A10-Q/ANov 9, 202310-Q/A10-Q/ANov 9, 202310-K/A10-K/ANov 9, 20238-KCompany UpdateNov 3, 20238-KExecutive Change · Company UpdateSep 5, 202310-Q10-QAug 14, 20238-KResults of Operations · Reg FD DisclosureAug 14, 20238-KExecutive ChangeAug 3, 20238-KShareholder VoteJun 13, 20238-KReg FD Disclosure · Company UpdateMay 25, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023
Insider Activity
In the 90 days to Mar 26, 2026: 1 insider bought $44K · 2 sold $6K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Shannon James SamuelDirector | Buy | 5,000 | $8.79 | $44K |
| Jan 2, 2026 | Frankenfield Christopher JamesChief Financial Officer | Sell | 7,030 | $0.64 | $4K |
| Jan 2, 2026 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Sell | 1,826 | $0.64 | $1K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance